Emergent BioSolutions Inc.
EBS
$8.50
-$0.45-5.03%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 112.45% | -206.64% | 526.67% | -117.65% | 317.25% |
| Total Depreciation and Amortization | 0.00% | 0.43% | -0.43% | -7.48% | -2.31% |
| Total Amortization of Deferred Charges | -30.77% | 4.00% | 4.17% | 4.35% | 4.55% |
| Total Other Non-Cash Items | -158.26% | 1,110.00% | 162.50% | -127.12% | 38.82% |
| Change in Net Operating Assets | -163.17% | 200.74% | -185.06% | 180.62% | -39.16% |
| Cash from Operations | -143.50% | 3,478.26% | -102.16% | 1,050.00% | 85.98% |
| Capital Expenditure | 38.46% | -14.71% | -17.24% | 19.44% | -111.76% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -99.74% | 12,600.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -100.00% | -20.00% | -16.67% |
| Cash from Investing | 38.46% | -14.71% | -119.77% | -71.09% | 108.04% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -1,430.43% | -- | -- | -- |
| Issuance of Common Stock | -66.67% | 500.00% | -71.43% | 600.00% | -87.50% |
| Repurchase of Common Stock | -24.21% | -3.26% | -29.58% | -1,320.00% | -66.67% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 89.99% | -616.35% | -148.44% | -1,500.00% | -180.00% |
| Foreign Exchange rate Adjustments | -- | 100.00% | -120.00% | 242.86% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -18.70% | -83.94% | -118.44% | 150.42% | 192.91% |